Eyenovia, Inc. (NASDAQ:EYEN – Get Free Report) saw a significant decrease in short interest in the month of July. As of July 31st, there was short interest totalling 2,710,000 shares, a decrease of 6.2% from the July 15th total of 2,890,000 shares. Based on an average daily trading volume, of 928,400 shares, the days-to-cover ratio is presently 2.9 days.
Eyenovia Price Performance
Shares of NASDAQ EYEN opened at $0.83 on Monday. The company has a market capitalization of $44.71 million, a PE ratio of -1.11 and a beta of 1.77. The company has a quick ratio of 0.66, a current ratio of 0.88 and a debt-to-equity ratio of 3.72. Eyenovia has a twelve month low of $0.50 and a twelve month high of $2.57. The firm has a fifty day simple moving average of $0.92 and a 200 day simple moving average of $1.07.
Insider Activity
In other Eyenovia news, major shareholder Stuart M. Grant bought 1,515,151 shares of Eyenovia stock in a transaction on Tuesday, July 2nd. The shares were purchased at an average cost of $0.66 per share, with a total value of $999,999.66. Following the acquisition, the insider now directly owns 10,914,153 shares of the company’s stock, valued at approximately $7,203,340.98. The acquisition was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. 7.10% of the stock is currently owned by insiders.
Institutional Inflows and Outflows
Analysts Set New Price Targets
Separately, HC Wainwright reaffirmed a “buy” rating and issued a $12.00 price objective on shares of Eyenovia in a research note on Tuesday, August 13th.
Check Out Our Latest Stock Analysis on Eyenovia
About Eyenovia
Eyenovia, Inc, an ophthalmic technology company, engages in the development of therapeutics based on its proprietary microdose array print platform technology. The company's product candidates include MicroPine, which is in Phase III clinical development program with indications for pediatric myopia progression (near-sightedness); MicroLine, which is in Phase III clinical development program with indications for the improvement in near vision in people with presbyopia; and Mydcombi, which is in Phase III clinical development program with indications for pharmaceutical mydriasis.
Recommended Stories
- Five stocks we like better than Eyenovia
- High Flyers: 3 Natural Gas Stocks for March 2022
- This Small Cap Wealth Management Stock Could Provide Big Returns
- How to Most Effectively Use the MarketBeat Earnings Screener
- Bumble’s Valuation Hits an All-Time Low, Can Its Fortunes Change?
- When to Sell a Stock for Profit or Loss
- MarketBeat Week in Review – 8/12 – 8/16
Receive News & Ratings for Eyenovia Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eyenovia and related companies with MarketBeat.com's FREE daily email newsletter.